Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Lymphoma 666Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Lymphoma, Follicular 418Lymphoma, Large B-Cell, Diffuse 379Leukemia 358Hodgkin Disease 354Lymphoma, Mantle-Cell 306Leukemia, Myeloid, Acute 250Multiple Myeloma 237Myelodysplastic Syndromes 214Lymphoma, B-Cell, Marginal Zone 196Recurrence 195Burkitt Lymphoma 189Waldenstrom Macroglobulinemia 155Leukemia, Myelogenous, Chronic, BCR-ABL Positive 130Lymphoma, B-Cell 127Neoplasms 118Lymphoma, T-Cell, Cutaneous 116Lymphoma, Large-Cell, Anaplastic 113Hematologic Neoplasms 103Lymphoma, Large-Cell, Immunoblastic 100Mycosis Fungoides 95Myeloproliferative Disorders 94Sezary Syndrome 86Lymphoma, T-Cell, Peripheral 83Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Lymphoma, T-Cell 74Primary Myelofibrosis 70

Interventions

rasburicase 2Urate Oxidase 1Allopurinol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hyperuricemia × Lymphoid × Clear all
NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
82 enrolled 6 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡